Beximco Pharmaceuticals Ltd Holdings in Company (9600U)
31 März 2023 - 12:03PM
UK Regulatory
TIDMBXP
RNS Number : 9600U
Beximco Pharmaceuticals Ltd
31 March 2023
31 March 2023
BEXIMCO PHARMACEUTICALS LIMITED
Holdings in Company
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, notes that two significant
shareholders in Bangladesh have reported a trade between one
another in the Company's Ordinary shares, which are only tradeable
in Bangladesh, to the Dhaka Stock Exchange on 22 March 2023. This
trade does not concern global depositary receipts admitted to
trading on AIM in London.
IFIC Securities Limited sold 17m Ordinary shares at a price of
TK. 135.00 per share to Absolute Construction and Engineering
Limited who bought the17m Ordinary shares at a price of TK. 135.00
per share between 14 and 20 March 2023.
As a result, IFIC Securities Limited now holds 4,780,000
Ordinary shares representing 1.07 per cent. of the total voting
rights in the Company and Absolute Construction and Engineering
Limited now holds 41,152,022 Ordinary shares representing 9.22 per
cent. of the total voting rights in the Company.
For further information, please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
Mohammad Asad Ullah FCS
Executive Director & Company Secretary
Tel: 880 2 58611001, Ext. 10140
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLGZGFFGMMGFZM
(END) Dow Jones Newswires
March 31, 2023 06:03 ET (10:03 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024